| Literature DB >> 24133396 |
Abstract
BACKGROUND: A national survey of patient exposure from nuclear medicine diagnostic procedures was performed by Slovenian Radiation Protection Administration in order to estimate their contribution to the collective effective dose to the population of Slovenia.Entities:
Keywords: collective effective dose; diagnostic procedures; dose per capita; nuclear medicine; population exposure
Year: 2013 PMID: 24133396 PMCID: PMC3794887 DOI: 10.2478/raon-2013-0048
Source DB: PubMed Journal: Radiol Oncol ISSN: 1318-2099 Impact factor: 2.991
Data about the 26 nuclear medicine examinations as selected by the Study on European Population Doses From Medical Exposure (DDM2) project
| Bone imaging | 99mTc | Phosphates, phosphonates | 7542 | 683 (550–700) | 5.70E-03 | 3.89 | 29.36 |
| Myocardial perfusion, rest | 99mTc | Tetrofosmin | 2700 | 591 (520–600) | 7.60E-03 | 4.49 | 12.13 |
| Myocardial perfusion, exercise | 99mTc | MIBI | 1936 | 583 (520–630) | 7.90E-03 | 4.61 | 8.92 |
| Myocardial perfusion, rest | 99mTc | MIBI | 1577 | 582 (520–630) | 9.00E-03 | 5.24 | 8.26 |
| Thyroid imaging (oral administration, no blocking) | 99mTc | Pertechnetate | 4546 | 97 (74–120) | 1.30E-02 | 1.26 | 5.73 |
| Myocardial perfusion, exercise | 99mTc | Tetrofosmin | 1370 | 580 (520–600) | 7.00E-03 | 4.06 | 5.56 |
| MUGA, cardiac blood pool, flow (equilibrium) | 99mTc | Tc-labelled erythrocytes | 608 | 923 (740–925) | 7.00E-03 | 6.46 | 3.93 |
| Myocardial perfusion | 201Tl | Chloride | 250 | 111 (111–111) | 1.40E-01 | 15.54 | 3.89 |
| Lung perfusion | 99mTc | MAA | 1518 | 143 (115–185) | 1.10E-02 | 1.57 | 2.38 |
| Infection/inflammation imaging | 99mTc | labbelled white blood cells | 303 | 483 (450–650) | 1.10E-02 | 5.31 | 1.61 |
| Parathyroid imaging | 99mTc | MIBI | 279 | 624 (444–777) | 9.00E-03 | 5.61 | 1.57 |
| Thyroid metastases (after ablation, uptake 0%) | 131I | Iodide | 118 | 148 (148–148) | 6.10E-02 | 9.03 | 1.07 |
| Tumor imaging (PET) | 18F | FDG | 1350 | 370 (370–370) | 1.90E-03 | 0.70 | 0.95 |
| Renal imaging | 99mTc | MAG 3 | 1126 | 116 (100–185) | 7.00E-03 | 0.81 | 0.92 |
| Dopamine transporter imaging (parkinsonism) | 123I | Ioflupane (DaTscan) | 223 | 121 (115–125) | 2.40E-02 | 2.89 | 0.65 |
| Neuroendocrine tumors/somatostatin receptors imaging | 111In | Pentetreotide (OctreoScan) | 30 | 222 (222–222) | 5.40E-02 | 11.99 | 0.36 |
| Infection/inflammation imaging | 67Ga | Gallium citrate | 16 | 177 (120–200) | 1.00E-01 | 17.68 | 0.27 |
| Infection/inflammation imaging | 99mTc | Monoclonal antibody (LeucoScan) | 48 | 553 (550–555) | 8.00E-03 | 4.42 | 0.21 |
| Myocardial perfusion (PET) | 18F | FDG | 30 | 300 (300–300) | 1.90E-02 | 5.70 | 0.17 |
| Cerebral blood flow | 99mTc | ECD (Neurolite) | 119 | 657 (555–700) | 2.20E-03 | 1.45 | 0.17 |
| Cerebral blood flow | 99mTc | Exametazime (HMPAO,Ceretec) | 22 | 700 (700–700) | 9.30E-03 | 6.51 | 0.14 |
| Thyroid imaging (thyroid uptake 35%) | 123I | Iodide | 278 | 15 (15–15) | 2.20E-02 | 0.34 | 0.09 |
| MUGA, cardiac blood pool, flow (equilibrium) | 99mTc | DTPA | 20 | 740 (740–740) | 4.90E-03 | 3.63 | 0.07 |
| Renal imaging | 99mTc | DTPA | 80 | 185 (185–185) | 4.90E-03 | 0.91 | 0.07 |
| Tumor imaging (PET) + Diagnostic CT | 18F | FDG | 81 | 370 (370–370) | 1.90E-03 | 0.70 | 0.06 |
| Renal imaging | 99mTc | DMSA | 32 | 91 (80–100) | 8.80E-03 | 0.80 | 0.03 |
|
| |||||||
DMSA = dimercaptosuccinic acid; DTPA = diethylene triamine pentaacetic acid; ECD = Neurolite; FDG = Fluorodeoxyglucose (18F); MAA = technetium 99mTc albumin aggregated; MIBI = technetium (99mTc) sestamibi; MUGA = multi gated acquisition scan
Data about the 10 additional nuclear medicine examinations with the highest contribution to the collective effective dose to the population from nuclear medicine procedures in Slovenia
| Myocardial perfusion, persantin | 99mTc | Tetrofosmin | 908 | 600 (600–600) | 1.12E-02 | 6.72 | 6.10 |
| Prostate imaging (PET) | 18F | Choline | 240 | 250 (250–250) | 3.13E-02 | 7.83 | 1.88 |
| Tumor imaging (PET) + Low dose CT | 18F | FDG | 1437 | 370 (370–370) | 1.90E-03 | 0.70 | 1.01 |
| Brain imaging (PET) | 18F | FDG | 203 | 250 (250–250) | 2.00E-02 | 5.00 | 1.01 |
| Labelled erythrocytes | 99mTc | Tc-labelled erythrocytes | 96 | 569 (450–600) | 1.40E-02 | 7.97 | 0.76 |
| Neuroendocrine tumors/somatostatin receptors imaging | 99mTc | EDDA/HYNIC-TOC | 174 | 600 (600–600) | 5.00E-03 | 3.00 | 0.52 |
| Pre-ablation thyroid remnant imaging (oral administration, no blocking) | 131I | Iodide | 135 | 4 (4–4) | 1.00E+00 | 3.70 | 0.50 |
| Liver hemangiom | 99mTc | Tc-labelled erythrocytes | 66 | 450 (450–450) | 1.40E-02 | 6.30 | 0.42 |
| Lung ventilation | 99mTc | Tctechnegas | 380 | 40 (40–40) | 2.43E-02 | 0.97 | 0.37 |
| Sentinel node | 99mTc | Nanocoll | 176 | 124 (74–133) | 1.70E-02 | 2.11 | 0.37 |
|
| |||||||
| Total | 3815 | 12.94 | |||||
EDDA/HYNIC-TOC = EDDA/HYNIC-Tyr3-octreotide; FDG = Fluorodeoxyglucose (18F)
FIGURE 1.Number of nuclear medicine examinations grouped according to the organ, target or closely similar objectives.
FIGURE 2.Collective effective dose from nuclear medicine examinations grouped according to the organ, target or closely similar objectives.
FIGURE 3.Number of nuclear medicine examinations according to the isotope used.
FIGURE 4.Collective effective dose from nuclear medicine examinations according to the isotope used.
FIGURE 5.Number of examinations per nuclear medicine department.
FIGURE 6.Collective effective dose (manSv) per nuclear medicine department.